Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.
Tianqing ChuJun LuMinghong BiHelong ZhangWu ZhuangYan YuJianhua ShiZhendong ChenXiaochun ZhangQisen GuoQuan LiuHuijuan WuJian FangYi HuXiuwen WangCuicui HanKai LiBao-Hui HanPublished in: Cancer biology & medicine (2021)
QL1101 showed similar efficacy and safety profiles as compared to bevacizumab among Chinese patients with untreated locally advanced non-squamous NSCLC.
Keyphrases
- double blind
- clinical trial
- placebo controlled
- phase iii
- phase ii
- locally advanced
- high grade
- open label
- low grade
- small cell lung cancer
- metastatic colorectal cancer
- squamous cell carcinoma
- study protocol
- phase ii study
- rectal cancer
- neoadjuvant chemotherapy
- cell therapy
- stem cells
- randomized controlled trial
- radiation therapy
- bone marrow
- tyrosine kinase
- lymph node
- mesenchymal stem cells